High-Pressure Hand Injection Injuries Caused by Dry Cleaning Solvents: Case Reports, Review of the Literature, and Treatment Guidelines

2003 ◽  
Vol 111 (1) ◽  
pp. 174-177 ◽  
Author(s):  
Karol A. Gutowski ◽  
Jason Chu ◽  
Mihye Choi ◽  
David W. Friedman
Author(s):  
Mateusz Kozłowski ◽  
Katarzyna Nowak ◽  
Agnieszka Kordek ◽  
Aneta Cymbaluk-Płoska

Carcinosarcoma, leiomyosarcoma, melanoma and carcinoid as primary tumors in the ovary are extremely rare. In this paper, the authors reviewed the literature from 2010 to 2021, based on specific criteria, to analyze the treatment of these rare ovarian neoplasms. We also aimed to verify whether modern therapies have been found in recent years. For this article, 80 papers were finally selected. The vast majority of the articles were clinical case reports. Despite single mentions of new potential pharmacological treatments, surgery (radical or fertility-sparing) is definitely the mainstay of treatment. There are currently no treatment guidelines for these tumors. A review of the literature has revealed the use of various adjuvant treatments. We, therefore, believe that a more detailed understanding of the biology of these tumors is necessary in order to find new target points for treatment. We would like to emphasize the importance of creating an international database of rare ovarian tumors which would make it possible to gather data from various oncological centers and enable further research into these neoplasms.


2017 ◽  
Vol 7 (2) ◽  
pp. 23
Author(s):  
Yusef A. Syed ◽  
Daniel H. Miller ◽  
Liuyan Jiang ◽  
Arya Bagherpour ◽  
Stephen J. Ko

Thymic neuroendocrine tumors are rare, representing less than 5% of all thymic cancers, and are biologically distinct in histology and behavior. Conclusive treatment guidelines are limited due to a lack of randomized clinical trials. Current literature, consisting mainly of case reports and series, suggests that complete surgical resection combined with adjuvant radiation therapy offers the greatest survival benefit for patients with thymic neuroendocrine tumors (NET). Adjuvant chemotherapy may also delay the onset of distant metastasis. Prognosis is generally poor, particularly in high-grade tumors, as these patients are prone to early metastasis. Here we present the case of a 62-year-old woman who achieved a durable response after undergoing an aggressive multimodal treatment approach for a primary thymic NET that initially presented as chronic cough and mild dyspnea on exertion.


2021 ◽  
Vol 29 (4) ◽  
pp. 213
Author(s):  
Bugra Ipek ◽  
Ugurcan Sener ◽  
Feridun Elmas ◽  
Ergin Seven ◽  
Aysegul Uslu ◽  
...  

2019 ◽  
Vol 19 (2) ◽  
pp. e271-e275 ◽  
Author(s):  
Sara Tanini ◽  
Alessandra D. Fisher ◽  
Icro Meattini ◽  
Simonetta Bianchi ◽  
Jiska Ristori ◽  
...  

Author(s):  
Márcia Marinho ◽  
Sara Nunes ◽  
Cátia Lourenço ◽  
Mónica Melo ◽  
Cristina Godinho ◽  
...  

2021 ◽  
Vol 81 ◽  
pp. 105720
Author(s):  
Youssef Oukessou ◽  
Yassir Hammouda ◽  
Khadija El Bouhmadi ◽  
Redallah Larbi Abada ◽  
Mohamed Roubal ◽  
...  

2021 ◽  
pp. 106002802110299
Author(s):  
S. Lena Kang-Birken

Objective: To evaluate recent publications on efficacy of single-dose azithromycin and 7-day doxycycline when treating Chlamydia trachomatis. Data Sources: A literature search of MEDLINE, EMBASE, PubMed, and Cochrane library was conducted (1990 to June 13, 2021) using the terms: Chlamydia trachomatis, genital chlamydia, rectal chlamydia, extragenital chlamydia, azithromycin, doxycycline, and treatment guidelines. ClinicalTrials.gov was searched to identify ongoing trials. Study Selection and Data Extraction: English language studies, including controlled studies, retrospective analyses, systematic reviews, meta-analyses, and case reports, reporting microbiological or clinical outcomes in adolescents and adults were considered. Data Synthesis: Systemic reviews and meta-analyses of randomized trials reported azithromycin efficacy of 96% to 97% in genital chlamydia. However, reports of treatment failure have emerged, especially among symptomatic males, with an increased risk of microbiological failure after azithromycin than doxycycline (relative risk = 2.45; 95% CI = 1.36-4.41). Retrospective analyses and prospective observational cohort studies reported lower efficacy range following azithromycin than doxycycline (74%-87% vs 92%-100%, respectively) in rectal chlamydia. First randomized controlled trial comparing azithromycin and doxycycline reported significantly higher microbiological cure following doxycycline, with absolute difference of 26% (95% CI = 16%-36%; P < 0.001). The proposed 2021 Centers for Disease Control and Prevention treatment guidelines designate doxycycline as the preferred agent for treatment at any site. Relevance to Patient Care and Clinical Practice: A growing body of evidence for treatment failure following azithromycin, especially in rectal chlamydia supports updating current practice. Conclusions: Doxycycline continues to achieve high efficacy in genital and rectal chlamydia. Clinicians should consider efficacy with convenience of dosing regimen, medication compliance, and sexual behavior risks when treating chlamydia infections.


1994 ◽  
Vol 152 (5 Part 1) ◽  
pp. 1568-1571 ◽  
Author(s):  
Joseph G. Borer ◽  
Kenneth I. Glassberg ◽  
E. George Kassner ◽  
David A. Schulsinger ◽  
Unni M.M. Mooppan

Sign in / Sign up

Export Citation Format

Share Document